A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.
about
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasTargeting CD19 in B-cell lymphoma: emerging role of SAR3419KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in MiceMYC and the control of DNA replication.A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.Comparison of mesenchymal stem cell markers in multiple human adult stem cellsCritical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.CD19 as a molecular target in CNS autoimmunity.Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyGalectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanismsEndoU is a novel regulator of AICD during peripheral B cell selection.Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression.CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.Targeting high-grade B cell lymphoma with CD19-specific T cells.Differences in metabolic biomarkers in the blood and gene expression profiles of peripheral blood mononuclear cells among normal weight, mildly obese and moderately obese subjects.Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.Genes and pathways associated with the occurrence of malignancy in benign lymphoepithelial lesions.Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer
P2860
Q26749139-DE42D3DC-15A5-4FB1-8440-3B2E49D726DCQ27027562-CD882BC2-4BA7-45E7-A9A5-E6E7F0D175F4Q28547671-B3891322-D2C5-425A-A2DD-18088F685F65Q33653686-260110B7-8DAC-47D2-9FDB-CD9B7A84016FQ33692070-A4399460-8D47-49FE-9BBE-D7DE65C97257Q34599681-0C311B19-D263-4CBC-9C6B-FE8B38ABE5F7Q34649044-4A710E65-5FDD-49C0-BE36-78DDC9D1D5A6Q34976749-E4CCC7DE-5CB0-4E52-A3F3-00ABE5B9D135Q36349583-0CCF4BF2-1054-4DCF-A352-CC5FD9324299Q36800456-D89BADE9-83C3-4EA5-85DA-6EC03959A61FQ37483153-25082A91-5C21-448D-9639-5AB7979B74A0Q37619947-E4A43293-C1D7-45E4-8C81-3944F2EC600FQ38064963-9F027B0A-8C04-4B81-85E0-833C38B2F74DQ38124065-78294044-CA67-4825-9D71-7D6DDCBC3486Q38371387-FAFF6510-860F-45B5-B17A-AFFC2B806E72Q39026731-3731F327-E256-4592-9BC2-04D116F6191AQ39511975-C23D8BC5-F30F-4432-AB48-24ACA9C0DCFBQ41270773-AE549F7C-3F1D-4466-96B4-940994EC4AFEQ47569368-C526A5AD-720D-4A26-98FA-AA59F94D0668Q54119905-E5E9CA73-897C-45C9-BF28-A710E289562CQ55283579-9826BF72-4510-47A6-A93C-6184D64DEC62Q58745901-F57902EB-817F-4BA7-96F4-A30025666CA8
P2860
A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A c-Myc and surface CD19 signa ...... pment and progression in mice.
@ast
A c-Myc and surface CD19 signa ...... pment and progression in mice.
@en
type
label
A c-Myc and surface CD19 signa ...... pment and progression in mice.
@ast
A c-Myc and surface CD19 signa ...... pment and progression in mice.
@en
prefLabel
A c-Myc and surface CD19 signa ...... pment and progression in mice.
@ast
A c-Myc and surface CD19 signa ...... pment and progression in mice.
@en
P2093
P2860
P356
P1476
A c-Myc and surface CD19 signa ...... pment and progression in mice.
@en
P2093
Evgueni I Kountikov
Jonathan C Poe
Karen M Haas
Thomas F Tedder
Veronique Minard-Colin
P2860
P304
P356
10.4049/JIMMUNOL.1201000
P407
P577
2012-07-23T00:00:00Z